



BIOMÉRIEUX

VIDAS®

Anti-HEV IgM & Anti-HEV IgG

For actionable patient reporting decisions



PIONEERING DIAGNOSTICS




# Did you know?

- 20 million** infections with hepatitis E virus (HEV)/year <sup>(1)</sup>
- 3.3 million** acute cases/year <sup>(1)</sup>
- 44,000** deaths in 2015 <sup>(1)</sup>

The most common cause of acute viral hepatitis worldwide <sup>(2)</sup>  
1 virus, 2 different epidemiological patterns:

- Genotypes 1 & 2 (■)**
  - Transmission via contaminated water
  - Large outbreaks
- Genotypes 3 (■) & 4 (■)**
  - Transmission via ingestion of undercooked meat
  - Sporadic cases
- Populations at risk**
  - Pregnant women (20/25% case fatality rates in 3<sup>rd</sup> trimester <sup>(1)</sup>)
  - Immunocompromised patients
  - Patients with pre-existing liver disease



## Think Hepatitis E!



### WHY?


- **Clinically undistinguishable** from other types of acute hepatitis
- Self-limiting disease in most cases, but can also be **fatal** in its **fulminant form**, in **pregnant women, infants** or patients with **pre-existing liver disease**
- Immunocompromised patients may develop chronic infection

### WHEN?

- First-line test for **acute hepatitis**
- All patients with **clinical signs and symptoms of hepatitis**
- All patients with biological signs of **cytolysis** (increase in serum transaminase levels)

### DIAGNOSIS

- Due to the **short period of HEV viremia**, diagnosis of HEV infection is mainly based on **specific anti-HEV IgM and IgG detection**.
- **Complementary detection of IgM and IgG antibodies:**
  - IgM to detect recent infection
  - IgG to detect recent or past infection



# VIDAS<sup>®</sup> Anti-HEV IgM & Anti-HEV IgG

## Offer even greater value to your clinicians!

### PERFORM HEPATITIS E TESTS IN YOUR OWN LAB

- Control the whole process: **your quality, your way**
- Streamline your workflow: save **time** and improve your lab **efficiency**
- Offer rapid and actionable results to your clinicians through **same-day complete hepatitis diagnosis** (A, B, C, E)

### BECAUSE IT MAKES SENSE ON VIDAS<sup>®</sup>

- **AUTOMATED** tests
- **On-demand** testing adapted to small volumes
- Result in **only 40 minutes**
- Cost-efficient solution: **1 patient = 1 test**

WITH VIDAS<sup>®</sup>  
INTEGRATE HEPATITIS E  
INTO YOUR ROUTINE  
TESTING

### EXCELLENT PERFORMANCE

**Clear result** for the diagnosis of acute hepatitis E:

VIDAS <sup>®</sup> Anti-HEV IgM QUALITATIVE Assay	VIDAS <sup>®</sup> Anti-HEV IgG QUANTITATIVE Assay
<b>97.65%*</b> Positive concordance for viremic phase	<b>96.67%*</b> Positive concordance
<b>99.34%*</b> Negative concordance	<b>96.42%*</b> Negative concordance

Evaluated  
by a National  
Reference Center  
for Hepatitis E

\* Immunocompetent population  
See package insert

AVAILABLE ON  
INSTRUMENTS OF  
THE VIDAS® FAMILY:  
VIDAS®, MINI VIDAS®  
AND VIDAS® 3



### VIDAS® HEPATITIS PANEL

#### HEPATITIS A

- HAV IgM
- Anti-HAV Total

#### HEPATITIS B

- HBs Ag Ultra
- HBs Ag Ultra Confirmation
- Anti-HBs Total II
- Anti-HBc Total II
- HBc IgM II
- HBe/Anti-HBe

#### HEPATITIS C

- Anti-HCV

#### HEPATITIS E

- Anti-HEV IgM
- Anti-HEV IgG

#### VIDAS® Anti-HEV IgM

#### VIDAS® Anti-HEV IgG

Reference number	418115	418116
Tests / kit	30	30
Time to result	40 minutes	40 minutes
Sample type	Serum, Plasma	Serum, Plasma
Sample volume	100 µL	100 µL
Calibrators & Controls frequency	Every 28 days	Every 28 days

#### REFERENCES

1. WHO, Hepatitis E Factsheet, July 2017.
2. N. Kamar, et al., Hepatitis E, Lancet 379 (9835) (2012) 2477–2488.